The City Council unanimously voted to ban the use of a class of rat poisons known as second-generation anticoagulant rodenticides, or SGARs, on city-owned property after a public hearing ...

High blood pressure stands among the leading causes of stroke, yet many people fail to recognize the critical importance of ...

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK ...

Cadrenal Therapeutics, Inc. , a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, with the late-stage asset tecarfarin, a new Vitamin K ...

Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ETCompany ParticipantsFrancesca DeMartino - Senior Vice President, ...

PONTE VEDRA, Fla. - Cadrenal Therapeutics, Inc. (NASDAQ: CVKD), a biopharmaceutical company specializing in cardiovascular therapies with a market capitalization of $35.2 million and impressive 210% ...

A New Therapeutic Target for a Lethal Form of Heart Failure ... 2025 — Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating ...

We aimed to assess and quantify current time metrics in anticoagulant-associated ICH (AAICH ... Mean admission systolic BP was 177.2±28.6 mmHg, with a 140 mmHg BP target in 94%. At 60 minutes from ...

Primary end point Efficacy end point is symptomatic stroke/systemic embolism Definition of the safety end point of bleeding differs across trials Prothrombin time international normalized ratio ...

Oral anticoagulant or antiplatelet medication use had no substantial effect on the accuracy of multitarget stool DNA testing for colorectal cancer, according to a study published in Gastro Hep ...

BMS acquired Cobenfy as part of its $14 billion takeover of Karuna Therapeutics towards the end of 2023, and analysts at ...